Connection
Kathleen Packard to Piperazines
This is a "connection" page, showing publications Kathleen Packard has written about Piperazines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.178 |
|
|
|
-
Ling H, Packard KA, Burns TL, Hilleman DE. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris. Am J Cardiovasc Drugs. 2013 Dec; 13(6):407-12.
Score: 0.083
-
Packard KA, Campbell JA, Knezevich JT, Davis EM. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome. Pharmacotherapy. 2012 Mar; 32(3):244-73.
Score: 0.074
-
DiNicolantonio JJ, Norgard NB, Meier P, Lavie CJ, O'Keefe JH, Niazi AK, Chatterjee S, Packard KA, D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Bangalore S, Fuchs FD, Serebruany VL. Optimal aspirin dose in acute coronary syndromes: an emerging consensus. Future Cardiol. 2014 Mar; 10(2):291-300.
Score: 0.021